The role of STAT3 in non-small cell lung cancer

Daijiro Harada, Nagio Takigawa, Katsuyuki Kiura

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Persistent phosphorylation of signal transducer and activator of transcription 3 (STAT3) has been demonstrated in 22%~65% of non-small cell lung cancers (NSCLC). STAT3 activation is mediated by receptor tyrosine kinases, such as epidermal growth factor receptor (EGFR) and MET, cytokine receptors, such as IL-6, and non-receptor kinases, such as Src. Overexpression of total or phosphorylated STAT3 in resected NSCLC leads to poor prognosis. In a preclinical study, overexpression of STAT3 was correlated with chemoresistance and radioresistance in NSCLC cells. Here, we review the role of STAT3 and the mechanisms of treatment resistance in malignant diseases, especially NSCLC. As STAT3 is a critical mediator of the oncogenic effects of EGFR mutations, we discuss STAT3 pathways in EGFR-mutated NSCLC, referring to mechanisms of EGFR tyrosine kinase inhibitor resistance.

Original languageEnglish
Pages (from-to)708-722
Number of pages15
JournalCancers
Volume6
Issue number2
DOIs
Publication statusPublished - 2014

Fingerprint

STAT3 Transcription Factor
Non-Small Cell Lung Carcinoma
Epidermal Growth Factor Receptor
Interleukin-6 Receptors
Cytokine Receptors
Receptor Protein-Tyrosine Kinases
Protein-Tyrosine Kinases
Transcriptional Activation
Phosphotransferases
Phosphorylation
Mutation

Keywords

  • Drug resistance
  • Epidermal growth factor receptor
  • Janus kinase 2
  • Non-small cell lung cancer
  • Signal transducer and activator of transcription 3

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

The role of STAT3 in non-small cell lung cancer. / Harada, Daijiro; Takigawa, Nagio; Kiura, Katsuyuki.

In: Cancers, Vol. 6, No. 2, 2014, p. 708-722.

Research output: Contribution to journalArticle

Harada, Daijiro ; Takigawa, Nagio ; Kiura, Katsuyuki. / The role of STAT3 in non-small cell lung cancer. In: Cancers. 2014 ; Vol. 6, No. 2. pp. 708-722.
@article{a839d3d3736e4e589469480ef6fec342,
title = "The role of STAT3 in non-small cell lung cancer",
abstract = "Persistent phosphorylation of signal transducer and activator of transcription 3 (STAT3) has been demonstrated in 22{\%}~65{\%} of non-small cell lung cancers (NSCLC). STAT3 activation is mediated by receptor tyrosine kinases, such as epidermal growth factor receptor (EGFR) and MET, cytokine receptors, such as IL-6, and non-receptor kinases, such as Src. Overexpression of total or phosphorylated STAT3 in resected NSCLC leads to poor prognosis. In a preclinical study, overexpression of STAT3 was correlated with chemoresistance and radioresistance in NSCLC cells. Here, we review the role of STAT3 and the mechanisms of treatment resistance in malignant diseases, especially NSCLC. As STAT3 is a critical mediator of the oncogenic effects of EGFR mutations, we discuss STAT3 pathways in EGFR-mutated NSCLC, referring to mechanisms of EGFR tyrosine kinase inhibitor resistance.",
keywords = "Drug resistance, Epidermal growth factor receptor, Janus kinase 2, Non-small cell lung cancer, Signal transducer and activator of transcription 3",
author = "Daijiro Harada and Nagio Takigawa and Katsuyuki Kiura",
year = "2014",
doi = "10.3390/cancers6020708",
language = "English",
volume = "6",
pages = "708--722",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "2",

}

TY - JOUR

T1 - The role of STAT3 in non-small cell lung cancer

AU - Harada, Daijiro

AU - Takigawa, Nagio

AU - Kiura, Katsuyuki

PY - 2014

Y1 - 2014

N2 - Persistent phosphorylation of signal transducer and activator of transcription 3 (STAT3) has been demonstrated in 22%~65% of non-small cell lung cancers (NSCLC). STAT3 activation is mediated by receptor tyrosine kinases, such as epidermal growth factor receptor (EGFR) and MET, cytokine receptors, such as IL-6, and non-receptor kinases, such as Src. Overexpression of total or phosphorylated STAT3 in resected NSCLC leads to poor prognosis. In a preclinical study, overexpression of STAT3 was correlated with chemoresistance and radioresistance in NSCLC cells. Here, we review the role of STAT3 and the mechanisms of treatment resistance in malignant diseases, especially NSCLC. As STAT3 is a critical mediator of the oncogenic effects of EGFR mutations, we discuss STAT3 pathways in EGFR-mutated NSCLC, referring to mechanisms of EGFR tyrosine kinase inhibitor resistance.

AB - Persistent phosphorylation of signal transducer and activator of transcription 3 (STAT3) has been demonstrated in 22%~65% of non-small cell lung cancers (NSCLC). STAT3 activation is mediated by receptor tyrosine kinases, such as epidermal growth factor receptor (EGFR) and MET, cytokine receptors, such as IL-6, and non-receptor kinases, such as Src. Overexpression of total or phosphorylated STAT3 in resected NSCLC leads to poor prognosis. In a preclinical study, overexpression of STAT3 was correlated with chemoresistance and radioresistance in NSCLC cells. Here, we review the role of STAT3 and the mechanisms of treatment resistance in malignant diseases, especially NSCLC. As STAT3 is a critical mediator of the oncogenic effects of EGFR mutations, we discuss STAT3 pathways in EGFR-mutated NSCLC, referring to mechanisms of EGFR tyrosine kinase inhibitor resistance.

KW - Drug resistance

KW - Epidermal growth factor receptor

KW - Janus kinase 2

KW - Non-small cell lung cancer

KW - Signal transducer and activator of transcription 3

UR - http://www.scopus.com/inward/record.url?scp=84897040895&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897040895&partnerID=8YFLogxK

U2 - 10.3390/cancers6020708

DO - 10.3390/cancers6020708

M3 - Article

AN - SCOPUS:84897040895

VL - 6

SP - 708

EP - 722

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 2

ER -